Comparing the efficacy and safety of apixaban compared to warfarin in patients with left ventricular thrombosis after acute myocardial infarctio
Phase 2
Recruiting
- Conditions
- eft ventricular thrombosis following acute myocardial infarction.Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarctionI23.6
- Registration Number
- IRCT20220809055645N1
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
All patients with left ventricular thrombosis within two weeks after acute myocardial infarction, if there is no contraindication to the use of anticoagulants
Exclusion Criteria
History of active bleeding,
History of coagulation disorders,
Contraindications to Apixaban or warfarin (For example, in patients with ESRD),
Drug sensitivity to Apixaban or warfarin,
Moderate to severe mitral stenosis,
Mechanical valve disease,
GFR less than 25,
If INR is not within the control-normal range, i.e. 2 to 3,
Consumption of drugs which interfere with Apixaban (such as amiodarone, antifungal drugs, anti-AIDS drugs, etc.)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of thrombosis and bleeding in patients with left ventricular thrombosis after acute myocardial infarction. Timepoint: At the beginning of the study, 3 months after the intervention. Method of measurement: By Echocardiography.
- Secondary Outcome Measures
Name Time Method Elimination of thrombus or change in size and its organization in the three-month follow-up, reduction of stroke and other thromboembolic events. Timepoint: Three months after the intervention. Method of measurement: By Echocardiography.